Cabaletta Bio Inc
NASDAQ:CABA
| Market Cap (Intraday) | 156.50M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $1.67 |
| 50-Day MA | $1.72 |
| 200-Day MA | $2.46 |
Cabaletta Bio Inc Stock, NASDAQ:CABA
2929 Arch Street, Suite 600, Philadelphia, Pennsylvania 19104
United States of America
Phone: +1.267.759.3100
Number of Employees: 103
Description
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.